XML 87 R44.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaboration Agreements - Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue (Detail)
$ in Thousands
Dec. 31, 2015
USD ($)
Astellas Agreement [Member] | Japan [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Cumulative Revenue $ 44,241
Deferred Revenue 28
Total Consideration 44,269
Astellas Agreement [Member] | Japan [Member] | License [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Cumulative Revenue 42,245
Deferred Revenue 0
Total Consideration 42,245
Astellas Agreement [Member] | Japan [Member] | When and if available compounds [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Cumulative Revenue 14
Deferred Revenue 28
Total Consideration 42
Astellas Agreement [Member] | Japan [Member] | Manufacturing-clinical supplies [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Cumulative Revenue 1,966
Deferred Revenue 0
Total Consideration 1,966
Astellas Agreement [Member] | Japan [Member] | Committee services [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Cumulative Revenue 16
Deferred Revenue 0
Total Consideration 16
Astellas Agreement [Member] | Europe [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Cumulative Revenue 443,692
Deferred Revenue 432
Total Consideration 444,124
Astellas Agreement [Member] | Europe [Member] | License [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Cumulative Revenue 401,316
Deferred Revenue 0
Total Consideration 401,316
Astellas Agreement [Member] | Europe [Member] | When and if available compounds [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Cumulative Revenue 332
Deferred Revenue 432
Total Consideration 764
Astellas Agreement [Member] | Europe [Member] | Manufacturing-clinical supplies [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Cumulative Revenue 9,612
Deferred Revenue 0
Total Consideration 9,612
Astellas Agreement [Member] | Europe [Member] | Committee services [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Cumulative Revenue 278
Deferred Revenue 0
Total Consideration 278
Astellas Agreement [Member] | Europe [Member] | Development services-in progress [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Cumulative Revenue 32,154
Deferred Revenue 0
Total Consideration 32,154
AstraZeneca Agreements [Member] | U.S./RoW [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Cumulative Revenue 340,160
Deferred Revenue 97,400
Total Consideration 437,560
AstraZeneca Agreements [Member] | U.S./RoW [Member] | License [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Cumulative Revenue 289,766
Deferred Revenue 0
Total Consideration 289,766
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Manufacturing-clinical supplies [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Cumulative Revenue 232
Deferred Revenue 70
Total Consideration 302
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Co-development, information sharing & committee services [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Cumulative Revenue 50,162
Deferred Revenue 37,936
Total Consideration 88,098
AstraZeneca Agreements [Member] | U.S./RoW [Member] | China-single unit of accounting [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Cumulative Revenue 0
Deferred Revenue 59,394
Total Consideration $ 59,394